| Item Type | Name |
|
Academic Article
|
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
|
|
Academic Article
|
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
|
|
Academic Article
|
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
|
|
Concept
|
Janus Kinase 1
|
|
Concept
|
Janus Kinase 3
|
|
Concept
|
Janus Kinase 2
|
|
Academic Article
|
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
|
|
Academic Article
|
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
|
|
Academic Article
|
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
|
|
Academic Article
|
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.
|
|
Academic Article
|
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
|
|
Academic Article
|
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
|
|
Academic Article
|
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
|
|
Academic Article
|
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
|
|
Academic Article
|
WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
|
|
Academic Article
|
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
|
|
Academic Article
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
|
Academic Article
|
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
|
Academic Article
|
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
|
|
Academic Article
|
Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
|
|
Academic Article
|
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.
|
|
Academic Article
|
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
|
|
Academic Article
|
Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.
|
|
Academic Article
|
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
|
|
Academic Article
|
Myelofibrosis osteoclasts are clonal and functionally impaired.
|
|
Concept
|
Janus Kinase Inhibitors
|
|
Academic Article
|
Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
|
|
Academic Article
|
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
|
|
Academic Article
|
The role of therapy in the outcome of patients with myelofibrosis.
|